![]() Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. This news release may contain forward-looking statements, including statements related to the proposed Acquisition and the anticipated indebtedness to be incurred in connection with the Acquisition, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. For more information, visit and connect with us on Twitter and LinkedIn. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. ![]() The Company has filed a Current Report on Form 8-K in connection with the above, a copy of which is also available on its SEDAR+ ( profile.īausch Health Companies Inc. ![]() In connection with the Acquisition, as previously disclosed, Bausch + Lomb anticipates incurring indebtedness (expected to be comprised principally of an incremental term loan and the issuance of senior secured notes), which is discussed in further detail in its Current Report on Form 8-K. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the "Acquisition") on a Current Report on Form 8-K and on its SEDAR+ ( profile. LAVAL, QC / ACCESSWIRE / Septem/ Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |